The treatment of severe premenstrual syndrome with goserelin with and without ‘add-back’ estrogen therapy: A placebo-controlled study

References

• O'Brien PMS. Helping women with premenstrual syndrome. Br Med J 1993; 307: 1471–5
   PubMedGoogle Scholar
• Frank R T. The hormonal basis of premenstrual tension. Arch Neurol Psychiatry 1931; 26: 1053–7
   Google Scholar
• Stickler R C. Endocrine hypothesis for the etiology of premenstrual syndrome. Clin Obstet Gynecol 1987; 30: 377–85
   Google Scholar
• Studd JWW. Premenstrual tension syndrome. Br Med J 1979; i: 410
   Google Scholar
• Backstrom T ,Boyle H ,Baird D T. Persistence of symptoms of premenstrual tension in hysterectomised women. Br J Obstet Gynaecol 1981; 88: 530–6
   PubMedGoogle Scholar
• Leather A T ,Holland EFN ,Andrews G N ,et al. A study of the referral patterns and therapeutic experiences of a hundred women attending a specialist premenstrual syndrome clinic. J R Soc Med 1993; 86: 199–201
   PubMed Web of Science ®Google Scholar
• Magos A L ,Brincat M ,Studd JWW. Treatment of the premenstrual syndrome by subcutaneous oestradiol implants and cyclical norethisterone: placebo controlled study. Br Med J 1986; 292: 1629–33
   PubMed Web of Science ®Google Scholar
• Watts J F ,Butt R W ,Logan Edwards R. A clinical trial using danazol for the treatment of premenstrual tension. Br J Obstet Gynaecol 1987; 94: 30–4
   PubMedGoogle Scholar
• Deeny M ,Hawthorn R ,McKay Hart D. Low dose danazol treatment of the premenstrual syndrome. Postgrad Med J 1991; 61: 450–4
   Google Scholar
• Watson N R ,Studd JWW ,Savvas M ,et al. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 1989; ii: 730–2
   Google Scholar
• Muse K N ,Cetal N S ,Futterman L A ,et al. The premenstrual syndrome effects of ‘medical ovariectomy’. N Engl J Med 1984; 311: 1345–9
   PubMed Web of Science ®Google Scholar
• Hammarback S ,Backstrom T. Induced anovulation as a treatment of premenstrual tension syndrome – a double blind crossover study with LRH-agonist versus placebo. Acta Obstet Gynecol Scand 1988; 67: 159–63
   PubMed Web of Science ®Google Scholar
• Hussain S Y ,Massil J H ,Matta W H ,et al. Buserlin in premenstrual syndrome. Gynecol Endocrinol 1992; 6: 57–64
   PubMed Web of Science ®Google Scholar
• Studd JWW ,Thorn M. Oestrogen and endometrial cancer. Progress in Obstetrics and Gynecology ,J Studd. Churchill Livingstone ,London 1981; 1: 182–98
   Google Scholar
• Magos A L ,Brewster E ,Singh R ,et al. The effect of norethisterone in post-menopausal women on oestrogen replacement therapy; a model for premenstrual syndrome. Br J Obstet Gynaecol 1986; 93: 1290–9
   PubMedGoogle Scholar
• Ganger K F ,Fraser D ,Whitehead M I ,et al. Prolonged endometrial stimulation with oestradiol implants. Br Med J 1990; 300: 436–8
   Google Scholar
• Watson N R ,Studd JWW ,Savvas M ,et al. The long-term effects of estradiol implant therapy for the treatment of premenstrual syndrome. Gynecol Endocrinol 1990; 4: 99–107
   PubMed Web of Science ®Google Scholar
• Dawood M Y ,Lewis V ,Ramos J. Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotrophin-releasing hormone agonist and danazol. Fertil Steril 1989; 52: 21–6
   Google Scholar
• Dodin S ,Lemay A ,Maheux R ,et al. Bone mass in endometriosis patients treated with GnRH agonist implant or danazol. Obstet Gynecol 1991; 7: 410–15
   Google Scholar
• Leather A T ,Studd JWW ,Watson N R ,et al. The prevention of bone loss in young women treated with GnRH analogs with ‘add-back’ estrogen therapy. Obstet Gynecol 1993; 81: 104–7
   PubMed Web of Science ®Google Scholar
• Comite F. GnRH analogs and safety. Obstet Gynecol Surv 1989; 44: 319–25
   Google Scholar
• Friedman A J. Treatment ofleiomyomata uteri with short-term leuprolide followed by leuprolide plus estrogen-progestin hormone replacement therapy for 2 years: a pilot study. Fertil Steril 1989; 51: 526–8
   PubMedGoogle Scholar
• Thomas E J ,Okuda K J ,Thomas N M. The combination of a depot gonadotrophin releasing hormone agonist and cyclical hormone replacement therapy for dysfunctional uterine bleeding. Br J Obstet Gynaecol 1991; 98: 1155–9
   PubMedGoogle Scholar
• Mortola J F ,Girton L ,Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotrophin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab 1991; 71: 252A–252F
   Web of Science ®Google Scholar
• Moos R H. The development of a menstrual distress questionnaire. Psychosom Med 1968; 30: 853–67
   PubMed Web of Science ®Google Scholar
• Magos A L ,Studd JWW. Assessment of menstrual cycle symptoms by trend analysis. Am J Obstet Gynecol 1986; 155: 271–7
   PubMed Web of Science ®Google Scholar
• Shaw R W ,Fraser H M ,Boyle H. Intranasal treatment with luteinizing hormone releasing hormone agonist in women with endometriosis. Br Med J 1983; 287: 1667–9
   Google Scholar
• Shaw R W ,Fraser H M. Use of a superactive luteinizing hormone releasing hormone (LHRH) agonist in the treatment of menorrhagia. Br J Obstet Gynaecol 1984; 91: 913–16
   PubMedGoogle Scholar
• West C P ,Lumsden M A ,Lawson S ,et al. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot. Fertil Steril 1987; 48: 45–51
   PubMed Web of Science ®Google Scholar
• Riis B J ,Christiansen C ,Johansen J S ,et al. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?. J Clin Endocrinol Metab 1990; 70: 920–4
   PubMed Web of Science ®Google Scholar
• Abdalla H ,Hart D M ,Lindsay R ,et al. The prevention of bone mineral loss in postmenopausal women by norethisterone. Obstet Gynecol 1985; 66: 789–92
   PubMed Web of Science ®Google Scholar
• Leather A T ,Studd JWW. Estrogen replacement therapy without the withdrawal bleed. Annual Progress in Reproductive Medicine ,R Asch ,J Studd. Parthenon Publishing ,CarnforthUK 1993; 291–300
   Google Scholar